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Abstract: A library of thirty novel thiazolo[5,4-f ]quinazolin-9(8H)-one derivatives belonging to
four series designated as 12, 13, 14 and 15 was efficiently prepared, helped by microwave-assisted
technology when required. The efficient multistep synthesis of methyl 6-amino-2-cyano-benzo[d]
thiazole-7-carboxylate (1) has been reinvestigated and performed on a multigram scale. The inhibitory
potency of the final products against five kinases involved in Alzheimer’s disease was evaluated.
This study demonstrates that some molecules of the 12 and 13 series described in this paper are
particularly promising for the development of new multi-target inhibitors of kinases.
Keywords: thiazolo[5,4-f ]quinazolin-9(8H)-ones; multi-target-directed ligand; protein kinases;
microwave-assisted synthesis; CDK5; GSK-3; CLK1; CK1; DYRK1A.
1. Introduction
Major human diseases such as cancer, neurodegenerative disorders and cardiovascular diseases
have been closely associated with the deregulation of kinases [1–3]. Consequently, protein kinases
represent pertinent targets for academic and industrial chemists searching for kinase inhibitors
as potential new therapeutic agents [4–6]. Most kinases phosphorylate both serine and threonine
residues, others phosphorylate tyrosines, and a small number phosphorylate all three amino acids
(dual-specificity kinases). Our research groups are mostly invested in the synthesis of sulfur- nitrogen
heteroaromatic molecules able to modulate the activity of deregulated kinases thought to be involved
in Alzheimer’s disease (AD) [7–15]. These five important kinases used in this study are the Ser/Thr
kinases (CDK5, GSK-3, CLK1 and CK1) and the dual-specificity kinases (DYRK1A family) [16–19].
The important impact of these kinases in various key cellular regulatory mechanisms is justifying
recent approaches consisting in the design of multi-target-directed ligands (MTDLs) [20–23] able to
target more than one kinase. This highly pertinent therapeutic strategy may allow the development of
new tools or therapies to better understand and treat patients suffering of neurodegenerative diseases.
In the course of our work, we previously described the synthesis of a small library of
8H-thiazolo[5,4-f ]quinazolin-9(8H)-ones (A in Figure 1) as dual CDK1/GSK-3 kinases inhibitors.
Brief studies of their inhibitory potency were realized with a small panel of kinases and showed two
compounds (I and II in Figure 2) with a micromolar range inhibitory effect on CDK1 and GSK-3 [7,8].
More recently, the synthesis and the kinase inhibitory potency of various N-arylbenzothieno[3,2-d]
pyrimidin-4-amines, and their pyrido and pyrazino analogues (B in Figure 1), have been published.
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These original heteroaromatics provide new means to target and inhibit some of the abovementioned
kinases in the nanomolar range [9–11].
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The overall pharmaceutical interest of all these compounds encouraged us to conceive new 
series of thiazolo[5,4-f]quinazolines substituted in position 4 of the pyrimidine ring by an aromatic 
amine and by carboximidamide or amidine groups in position 2 of the thiazole moiety [6,12–15] (see 
general formula C in Figure 1). These compounds were conceived as 6,6,5-tricyclic homologues of the 
basic 4-aminoquinazoline pharmacophore which is present in approximately 80% of ATP-competitive 
kinase inhibitors that have received approval for the treatment of cancer [4,5]. Five of the novel 
thiazolo[5,4-f]quinazoline derivatives prepared displayed single-digit nanomolar or subnanomolar IC50 
values and are among the most potent and selective DYRK1A/1B inhibitors disclosed to date [13–15]. 
Returning to our initial work [7,8] and extending the list of targeted kinases, we discovered that 
compounds I and II exhibit micromolar IC50 values against DYRK1A (Figure 2). This result suggested 
the possibility to extend the scope of pertinent kinases that these ligands are able to target.  
The results of various docking studies realized to understand the structure-activity relationships 
(SARs) are represented in Figure 2 and concern the ATP-binding site of GSK-3β [7,8,24]. They suggest 
that the unencumbered nitrogen in position 6 of the tricyclic core can form a hydrogen bond with the 
backbone NH-residue of Val135 in the hinge segment. This region of kinases ATP-binding site is 
considered as a critical H-bonded system with the majority of inhibitors that have been published to date. 
As described in Figure 2, a benzylcarbimidate function may form polar interaction between nitrogen atom 
of the imidate and the ammonium group of Lys85. In this hypothesis a bulky substituent at the R2 
position may not fit into the hydrophobic back-pocket of GSK-3β. This region of kinases ATP-binding site 
is known to not be conserved among kinases and can thus be used to gain affinity as well as selectivity.  
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Figure 2. Schematic representation of the proposed binding mode of compound I in the ATP-binding
site of GSK-3β.
The overall pharmaceutical interest of all these compounds encouraged us to conceive new
series of thiazolo[5,4-f ]quinazolines substituted in position 4 of the pyrimidine ring by an aromatic
amine and by carboximidamide or amidine groups in position 2 of the thiazole moiety [6,12–15]
(see general formula C in Figure 1). These compounds were conceived as 6,6,5-tricyclic homologues of
the basi 4-ami oqui azoline pharmacophore which is present in approximately 80% of ATP-competitive
kinase inhibitors that have received a proval for the treatment of c ncer [4,5]. Five of the novel
thiazolo[5,4-f ]quinazoline derivatives prepared displayed single-digit nanomolar or subnanomolar IC50
values and are among the most potent and selective DYRK1A/1B inhibitors disclosed to date [13–15].
Returning to our initial work [7,8] and extending the list of targeted kinases, we discovered that
compounds I and II exhibit micromolar IC50 values against DYRK1A (Figure 2). This result suggested
the possibility to extend the scope of pertin nt kinases that these ligands ar able to target.
The results of various docking studies realized to understand the structure-activity relationships
(SARs) are represented in Figure 2 and concern the ATP-binding site of GSK-3β [7,8,24]. They suggest
that the unencumbered nitrogen in position 6 of the tricyclic core can form a hydrogen bond with
the backbone NH-residue of Val135 in the hinge segment. This region of kinases ATP-binding site is
considered as a critical H-bonded system with the majority of inhibitors that have been published
to date. As described in Figure 2, a benzylcarbimidate function may form polar interaction between
nitrogen atom of the imidate and the ammonium group of Lys85. In this hypothesis a bulky substituent
at the R2 position may not fit into the hydrophobic back-pocket of GSK-3β. This region of kinases
ATP-binding site is known to not be conserved among kinases and can thus be used to gain affinity as
well as selectivity.
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As depicted in Figure 3, modulating the size and/or the nature of R1 and R2 may have an effect
on the affinity of the ligands by allowing cis- or trans-spatial positions of these groups in the targeted
binding sites. In the latest case, R2 group will be able to fit into the back-pocket of kinases and
concomitantly, the R2 group present on N8 may also influence the position of the inhibitor into the
enzyme site.
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Considering all these facts, the synthetic route to the thiazolo[5,4-f ]quinazolin-9(8H)-one scaffold
was optimized with the aim of modulating the R1 and R2 groups. This was expected by substituting the
position 8 of the pyrimidine ring with various alkyl and aryl groups and by introducing various alkyl
substituents on the carbimidate groups in position 2 of the thiazole moiety. Concerning this last point,
the choice of the aliphatic chains for R1 was inspired by previous results (see compounds C in Figure 1)
showing that small size groups can help to enhance the inhibitory activity against kinases [13].
This paper describes the development of a simple and reliable method allowing the preparation
of a library of new thiazolo[5,4-f ]quinazolin-9(3H)-ones for which interesting multi-target kinase
inhibitory activities were observed. The main part of the chemistry described in this paper was
achieved under microwave irradiation as a continuation of our global strategy consisting in the design
of appropriate reagents and techniques offering operational, economic, and environmental benefits
over conventional methods [25–27].
2. Results and Discussion
2.1. he istry
e tar et lec les ere thiazolo[5,4-f ] i az li -9(8 )- es s stit te i siti 8
( ic c rres s t siti 4 f t e ri i i e ri ) a ali atic c ai r a ar atic
s stit e t (Scheme 1). In order to reach a efficient route to these various 8-substituted
thiazol [5,4-f ]quinazolin-9(8H)-ones, a rational multistep synthesis of a novel polyfuncti nalized
benzothiazole (see 1 in Scheme 1) has been developed [28–30]. This molecular system was conceived to
be a versatile efficient prec rsor to various target molecules. The presence of the carbonitrile function
in position 2 of the thiazole ring should all w easy access to (alkyl)carbimidate functio and the
ortho-aminobenzoïc ester part should access to the target N8-substituted pyrimidin-4-one derivatives.
Molecules 2016, 21, 578 4 of 19
Molecules 2016, 21, 578 4 of 19 
 
 
Scheme 1. Envisioned transformations of 1 for synthesis of novel compounds of series A. 
Based on our previous studies [25–27], the synthesis of the key intermediate 1 was revised and 
optimized in six steps according to the procedure depicted in Scheme 2. N2-Protection of methyl  
5-nitroanthranilate (2) [31] provided methyl 2-[di(tert-butoxycarbonyl)amino]-5-nitrobenzoate (3), which 
was reduced by treatment with ammonium formate in the presence of a catalytic amount of 10% 
palladium charcoal. The resulting aromatic amine (4) was treated with N-bromosuccinimide (NBS) in 
DMF to give 5 and 6 (ratio 5/6: 9/1) in a quantitative yield. The mixture of ortho-bromo anilines 5 and 6 
was reacted with Appel’s salt (4,5-dichloro-1,2,3-dithiazolium chloride) to give intermediate imino-
1,2,3-dithiazoles 7 and 8 which were separated and purified by flash-column chromatography on silica 
gel. The intermediate imine 7 was transformed into the target methyl 6-amino-2-cyanobenzo[d]thiazole-
7-carboxylate (1) after N2-deprotection (giving 9, 96%) and microwave-assisted copper-mediated 
cyclization. This synthetic route allowed an efficient and reproducible preparation of 1, in a good 
overall yield of 43%, helped in some steps by microwave-assisted heating. In terms of efficiency, 20 g 
of 2-methyl 5-nitroanthranilate (2) may lead to 6 g of polyfunctionalized benzo[d]thiazole 1. 
 
Scheme 2. Multistep synthesis of the key benzothiazole 1. Reagents and conditions: (a) Boc2O (2.3 equiv), 
DMAP (1.0 equiv), Et3N (1.0 equiv), THF, r.t., 5 h; (b) HCO2NH4 (5.0 equiv), Pd/C (10%), EtOH, 78 °C 
(μw), 15 min; (c) NBS (1.0 equiv), DMF, −10 °C, 3 h; (d) Appel salt (1.2 equiv), Py. (2.3 equiv), CH2Cl2, 
r.t., 3 h; (e) TFA, CH2Cl2, r.t., 2 h; (f) CuI (1.0 equiv), Py., 115 °C (μw), 30 min. 
Treatment of 1 with 1.5 equiv of Vilsmeier-Haack reagent in dichloromethane at room temperature 
gave (E)-methyl 2-cyano-6-([(dimethylamino)methylene]amino)benzo[d]thiazole-7-carboxylate (10) 
in excellent yield (90%). This efficient synthesis can be performed at the multi-gram scale, enabling 
preparation of several grams of the key precursor 10. The aforementioned formimidamide was heated 
at 100 °C under microwave irradiation, in the presence of 1.05 equiv of appropriate amines, in acetic 
acid. After irradiation times of 6 to 10 min, cyclization of the pyrimidin-4-one part of the tricyclic 
product allowed access to the expected N8-substituted-9-oxo- 8,9-dihydrothiazolo[5,4-f]quinazoline-
2-carbonitriles (series 11) in moderate to good yields (58%–84%). Considering previous kinetics 
studies [32], it may be assumed that the mechanism of cyclization occurred via a first attack of the amine 
on the activated carbon of the amidine. The intermediate triamine species released dimethylamine and 
cyclized into the expected quinazolin-4-one derivatives (Scheme 3). 
Scheme 1. Envisioned transformations of 1 for synthesis of novel compounds of series A.
Based on our previous stu ies [25–27], the synthesis of the key intermediate 1 was revised and
optimized i six steps according to the procedu e depicted i Scheme 2. N2-Protection of methyl
5-nitro nthranilate (2) [31] provided ethyl 2-[di( ert-butoxycarbonyl)amino]-5-nitrobenzoate (3),
which was reduced by treatment with ammonium formate in the presence of a catalytic amount of
10% palladium charcoal. The resulting aromatic amine (4) was treated with N-bromosuccinimide
(NBS) in DMF to give 5 and 6 (ratio 5/6: 9/1) in a quantitative yield. The mixture of ortho-bromo
anilines 5 and 6 was reacted with Appel’s salt (4,5-dichloro-1,2,3-dithiazolium chloride) to give
intermediate imino-1,2,3-dithiazoles 7 and 8 which were separated and purified by flash-column
chromatography on silica gel. The intermediate imine 7 was transformed into the target
methyl 6-amino-2-cyanobenzo[d]thiazole-7-carboxylate (1) after N2-deprotection (giving 9, 96%)
and microwave-assisted copper-mediated cyclization. This synthetic route allowed an efficient
and reproducible preparation of 1, in a good overall yield of 43%, helped in some steps by
microwave-assisted heating. In terms of efficiency, 20 g of 2-methyl 5-nitroanthranilate (2) may
lead to 6 g of polyfunctionalized benzo[d]thiazole 1.
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Scheme 2. Multistep synthesis of the key benzothiazole 1. Reagents and conditions: (a) Boc2O (2.3 equiv),
DMAP (1.0 equiv), Et3N (1.0 equiv), THF, r.t., 5 h; (b) HCO2NH4 (5.0 equiv), Pd/C (10%), EtOH, 78 ˝C
(µw), 15 min; (c) NBS (1.0 equiv), DMF, ´10 ˝C, 3 h; (d) Appel salt (1.2 equiv), Py. (2.3 equiv), CH2Cl2,
r.t., 3 h; (e) TFA, CH2Cl2, r.t., 2 h; (f) CuI (1.0 equiv), Py., 115 ˝C (µw), 30 min.
Treatment of 1 with 1.5 equiv of Vilsmeier-Haack reagent in dichl romethane at ro m temperature
gave (E)-methyl 2-cyano-6-([(dimethylamino)methylene]amino)benzo[d]thiazole-7-carboxylate (10)
in excellent yield (90%). This efficient synthesis can be performed at the multi-gram scale, enabling
preparation of several grams of the key precurs r 10. The aforementioned formimida id was
heated at 100 ˝C under microwave rradiat on, in the p esence of 1.05 equiv of appropr ate amines,
in acetic acid. Aft r irra iation times of 6 to 10 min, cyclization of the pyrimidin-4-one part
of the tricyclic product allowed access to the expected N8-substituted-9-oxo- 8,9-dihydrothiazolo
[5,4-f ]quin zolin -2-carbonitriles (series 11) in oderate to good yields (58%–84%). Considering
previous kinetics studies [32], it may be assumed that the mechanism of cyclization occurred via a first
attack of the amine on the activated carbon of the amidine. The intermediate triamine species released
dimethylamine and cyclized into the expected quinazolin-4-one derivatives (Scheme 3).
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of various carbimidates were extended to ethyl, isopropyl, and benzyl derivatives using the same 
procedure and the appr priate alc hol (Scheme 4). 
The synthesis of f rty-fo r 8-susbtituted thiazolo[5,4-f]quinazo n-9(8H)-one derivatives was 
performed with suc ss. This process w  helped by the use of methyl 6-amino-2-cyano- benzo[d]thiazole-
7-carboxylate (1) [27], a molecular platform conceived to be a versatile and efficient precursor to 
various target molecules. Note that microwave heating was mainly performed at atmospheric 
pressure in a controlled multimode cavity with a microwave power delivery system ranging from 0 to 
1200 W. Concerning the technical aspects, open-vessel microwave experiments have some advantages, 
such as the possibility of easier scale-up and the use of common laboratory glassware. 
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a Reaction time is 10 min, except for 11k, 11l and 11m (6 min). b Isolated yield. 
At the last stage of the synthesis, transformati n of the carbonitrile group into a methylcarbimidate 
was realized by stirring compounds 11a–n ith sodium h droxide (2.5 M in water) i  methanol at 
room temperature for 1 h (Scheme 4). Methyl 9- xo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidates 
(12a–n) were thus obtained in good to exc llent yields (Table 2). In the course f SAR studies, libraries 
of various carbimidates were exten ed t  ethyl, is propyl, an  benzyl derivativ s using the same 
procedure and the appropriate alc ol (Scheme 4). 
The synthesis of forty-four 8- usb ituted thiaz lo[5,4-f]quinazolin-9(8H)-one derivatives was 
pe formed with success. This process was helped by the use of methyl 6-a ino-2-cyano- benzo[d]thiazole-
7-carboxylate (1) [27], a molecular platform conceived to be a versatile and efficient precursor to 
various target molecules. Note that microwave he ting was mainly performed at atmosp ric 
pressure in a controlled multimode cavity with a microw ve power deliver  system ranging from 0 to 
1200 W. Concerning th  technic l aspects, open-v ssel microwave experiments have some ad antages, 
such as the possibility of easier scale-up and the use of co mon laboratory glassware. 
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a Reaction time is 10 min, except for 11k, 11l and 11m (6 min). b Isolated yield. 
At the last stage of the synthesis, transformation of the carbonitrile group into a methylcarbimidate 
was realized by stirring compound  11a–  with sodium ydroxide (2.5 M i  w ter) i  meth n l at 
room temperature for 1 h (Sche e 4). Methyl 9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidates
(12a–n) were thus obtained in good to exc llent yields (Table 2). In the course of SAR studies, li rari  
of various ca bimidates were exten ed to thyl, isopropyl, and benzyl erivatives using the same 
pr cedure and the appropriate alcohol (Sch me 4). 
The sy thesis of f rty-four 8-susbtituted thiazolo[5,4-f]quin zolin-9(8H)-one derivativ s was 
perform d wit  succe s. This process was help  by the use of methyl 6-amino-2-cyano- b nzo[d]th az le-
7-carboxylate (1) [27], a molecular platform conceived t  be a ver atile and efficient precursor t  
various targ t molecules. N t  th t micr wave heating was mainly perform d t at ospheric 
press re in a con rolled multimode cavi y with a microw ve po er delivery system ranging from 0 to 
1200 W. Concer ing the technical asp ts, open-vessel microwave exp ri ents have some advantages,
such as the possibil ty of easier s e-up and the us  of commo  laboratory gla sware. 
11d 58
Molecules 2016 21, 578 5 of 19 
 
 
Sch me 3. Synthesis of s ries 11 compounds and sugg sted mechanism of cyclization after ttack of 
the primary amine. F r yields see Table 1. 
Table 1. Chemical str ctures and yiel ined for the synthesis of series 11a–n a. 
 
Compound Yield b (%) Compound Yield b (%) 
 11a 78  11h 84 
 11b 82  11i 77 
 11c 80 11j 78 
 1d   
11k 85 
 11e 70 11l 77 
 11f 73 11m 81 
 
11g 69  11n 84 
a Reaction time is 10 min, xcept for 11k, 11l and 11m (6 min). b Isolated yield. 
At the last stage of the synthesis, transformati n of the carbonitrile group into a methylcarb midate 
was realized by stirring compounds 11a–n with sodium hydroxide (2.5 M  w ter) in etha l at
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a Reaction time is 10 min, except for 11k, 11l and 11m (6 min). b Isolated yield. 
At the last stage of the synthesis, transformation of the carbonitrile group into a methylcarbimidate 
was realized by stirring compou d  11a–  with sodium ydroxide (2.5 M i  w ter) in meth nol at 
room temperat re for 1 h (Sche  4). Methyl 9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidates
(12a–n) wer  thus obtained in good to exc llent yields (Table 2). In the course of SAR studies, li rari  
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a Reaction time is 10 min, except for 11k, 11l and 11m (6 min). b Isolated yield. 
At the last stage of the synthesis, transformation of the carbonitrile group into a methylcarbimidate 
was realized by stirring compounds 11a–n with sodium hydroxide (2.5 M in water) in methanol at 
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Scheme 4. General synthesis of carbimidates 12, 13, 14 and 15 from 11 series (for yields see Table 2). 
Table 2. Synthesis of carbimidates 12, 13, 14 and 15 from 11 series. 
Product Yield a (%) Product Yield a (%) Product Yield a (%) Product Yield a (%)
12a 91 12h 70 13a 87 14a 93 
12b 71 12i 80 13b 58 14b 76 
12c 76 12j 86 13c 55 14c 72 
12d 92 12k 68 13d 65 14d 80 
12e 89 12l 74 13e 90 14e 92 
12f 76 12m 82 13f 86 15a 88 
12g 92 12n 90 13g 94 15b 65 
- - - - 13h 62 15c 90 
a Isolated yield. 
2.2. Biological Studies 
Products of series 11a–c, 12a–n, 13a–h, 14a–e and 15a–c were tested in five different in vitro 
kinase assays (CDK5/p25 (cyclin-dependent kinase), CK1δ/ε casein kinase 1), GSK-3α/β glycogen 
synthase kinase 3), DYRK1A (dual-specificity, tyrosine phosphorylation regulated kinase) and CLK1 
(cdc2-like kinase 1) to evaluate their inhibition potency [33–37]. All compounds were first tested at a 
final concentration of 10 μM. Compounds showing less than 50% inhibition were considered as 
inactive (IC50 >10 μM). Compounds displaying more than 50% inhibition at 10 μM were next tested 
over a wide range of concentrations (usually 0.01 to 10 μM), and IC50 values were determined from 
the dose-response curves (Sigma-Plot). Harmine (Table 3) is a β−carboline alkaloid known to be a 
potent inhibitor of DYRK1A [38]. It was also tested as positive control and its IC50 values were 
compared to those obtained for the compounds under study. 
Results given in Table 3 demonstrate that none of the tricyclic derivatives prepared in this work 
showed significant inhibitory activity against CDK5/p25 and CK1δ/ε. Only three compounds of 11a–c 
series are described in Table 3 and none of them showed any significant activity against the targeted 
kinases. These results are consistent with previous studies [7,8]. 
The results of the kinases inhibition potential obtained with compounds of the 14a–e and 15a–c 
series were also quite disappointing. Apart from product 14e, which exhibits a good and selective 
inhibition of GSK-3 (IC50 = 0.029 μM) and product 15a, which revealed a fairly good inhibition of 
CLK1 (IC50 = 0.043 μM), the IC50 values obtained for the other compounds of these two series (14a–d, 
15b and 15c) were not significant. 
In general, interesting and significant biological activity of the tested compounds was oriented 
towards three kinases of the initial panel: CLK1, DYRK1A and GSK-3α/β. 
Undoubtedly, the most active molecules prepared in this study were series 12 and 13 in which 
the final carbimidate function was obtained after attack of methanol or benzyl alcohol. Most of these 
compounds from these two series showed submicromolar activities against CLK1, DYRK1A and 
GSK-3α/β, except product 12m which was completely inactive (IC50 > 10 μM for the five kinases tested). 
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Table 2. Synthesis of carbimidates 12, 13, 14 and 15 from 11 series.
Product Yield a (%) Product Yield a (%) Product Yield a (%) Product Yield a (%)
12a 91 12h 70 13a 87 14a 93
12b 71 12i 80 13b 58 14b 76
12c 76 12j 8 13c 55 14c 72
12d 92 12k 68 13d 65 14d 80
12e 89 12l 74 13e 90 14e 92
12f 76 12m 82 13f 86 15a 88
12g 92 12n 90 13g 94 15b 65
- - - - 13h 62 15c 90
a Isolated yield.
2.2. Biological Studies
Product of eries 11a–c, 12a– , 13a–h, 14a–e nd 15a–c were tested in five different in vitro kinase
assays (CDK5/p25 (cyclin-dependent kinase), CK1δ/ε casein kinase 1), GSK-3α/β glycogen synthase
kinase 3), DYRK1A (dual-specificity, tyrosine phosphorylation regulated kinase) and CLK1 (cdc2-like
kinase 1) to evaluate their inhibition potency [33–37]. All compounds were first tested at a final
concentration of 10 µM. Compounds showing less than 50% inhibition were considered as inactive
(IC50 >10 µM). Compounds displaying more than 50% inhibition at 10 µM were next tested over a
wide range of concentrations (usually 0.01 to 10 µM), and IC50 values were determined from the
dose-response curves (Sigma-Pl t). Har ine (Table 3) is a β´carboline alkaloid known to be a potent
inhibitor of DYRK1A [38]. It was also test d as p sitive control an its IC50 values were compared to
those obtained for the comp unds under study.
Results given in Table 3 demonstrate that none of the tricyclic derivatives prepared in this work
showed significant inhibitory activity against CDK5/p25 and CK1δ/ε. Only three compounds of 11a–c
series are described in Table 3 and none of them showed any significant activity against the targeted
kinases. These results are consistent with previous studies [7,8].
The results of the kinases inhibition potential obtained with compounds of the 14a–e and 15a–c
series were also quite disappointing. Apart from product 14e, which exhibits a good and selective
inhibition of GSK-3 (IC50 = 0.029 µM) and produ t 15a, which r vealed a fairly good inhibition of
CLK1 (IC50 = 0.043 µM), the IC50 v ues obtained for the other compounds of these two series (14a–d,
15b and 15c) were not significant.
In general, interesting and significant biological activity of the tested compounds was oriented
towards three kinases of the initial panel: CLK1, DYRK1A and GSK-3α/β.
Undoubtedly, the most active molecules prepared in this study were series 12 and 13 in which
the final carbimidate function was obtained after attack of methanol or benzyl alcohol. Most of these
compounds from these two series showed submicromolar activities against CLK1, DYRK1A and
GSK-3α/β, except product 12m which was completely inactive (IC50 > 10 µM for the five kinases
tested). Curiously, despite the size modification of the carbimidate substituents, similar activity profiles
can be observed for the 12 and 13 series (see Table 3 in which the most significant results are underlined
in grey and significant IC50 values in the nanomolar range written in bold). It appears that the most
significant results were obtained with compounds of the a and d–g series in the two family products
(12 and 13).
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Table 3. Kinase inhibitory activity a,b of the thiazolo[5,4-f ]quinazoline series 11a–c, 12a–n, 13a–h,
14a–e, 15a–c.
Compounds CDK5/p25 CK1δ/ε CLK1 DYRK1A GSK-3α/β
11a >10 >10 1.1 3.3 3.3
11b >10 >10 4.1 7.8 ě10
11c >10 >10 1.3 7.7 1.2
12a 3.9 >10 0.031 0.091 0.082
12b >10 >10 0.51 0.39 1.2
12c >10 >10 0.21 0.32 0.12
12d 3.0 5.4 0.16 0.14 0.041
12e 4.9 >10 0.29 0.072 0.028
12f >10 >10 0.091 0.13 0.16
12g 1.8 >10 0.38 0.17 0.030
12h >10 >10 0.99 0.5 0.3
12i >10 >10 1.8 1.0 1.8
12j >10 >10 0.69 0.2 1.2
12k >10 >10 0.88 0.38 0.51
12l >10 >10 7.9 3.0 1.20
12m >10 >10 >10 >10 ě10
12n >10 >10 0.080 0.18 1.7
13a >10 >10 0.06 0.06 0.1
13b >10 >10 0.59 0.29 0.69
13c >10 >10 0.48 0.16 0.11
13d >10 >10 0.27 0.13 0.057
13e >10 >10 0.32 0.062 0.028
13f >10 >10 0.071 0.059 0.071
13g >10 >10 1.30 0.28 0.083
13h >10 >10 1.40 0.21 0.15
14a >10 >10 0.1 0.21 0.2
14b >10 >10 1.9 0.82 1.2
14c >10 >10 0.49 0.37 0.17
14d >10 >10 0.34 0.37 0.17
14e >10 >10 0.78 0.23 0.029
15a >10 >10 0.043 0.42 0.42
15b >10 >10 2.1 3.9 2.5
15c >10 >10 1.2 0.95 0.27
Harmine >10 1.5 0.026 0.029 >10
a IC50 values are reported in µM. The most significant results are presented in bold; b Kinases activities were
assayed in triplicate. Typically, the standard deviation of single data points was <10%.
Results obtained with compounds 12h–l (CLK1: 0.691 µM < IC50 < 7.9 µM), DYRK1A
(0.2 µM < IC50 < 3.0 µM) and GSK-33 α/β (0.3 µM < IC50 < 1.8 µM) demonstrated the necessity to
conserve a cyclic alkyl group in position 8 of the tricyclic core (12a and 12d–g), in order to maintain
good to very good affinity. The presence of basic groups in N8 (12h–j) may be correlated with an rather
important decrease of affinity, in the same way as the presence of aromatic substituents in position 8 of
the thiazolo[5,4-f ]quinazolin-9(8H)-one core (compounds 12k–m). In this last case, it appeared that
the nature of the substituents present in the para-position of the phenyl group in N8 may influence
and decrease the IC50 values measured for the various kinases. Compared with data obtained for
compounds in the 12d–g series, it seems to be the consequence to steric influence rather than electronic
effects. Compounds 12b, 12c and 13b, 13c were also analyzed and although their inhibitory activity
towards the three kinases (CLK1, DYRK1A and GSK-3α/β) was characterized by submicromolar
values of IC50, their global activity was considered not significant enough to continue further studies.
Comparison of the substituents present on N8 position of a and d–f series shows mainly a
small-size ring (e.g., cyclopropyl for 12a and 13a series) or its equivalent such as isopropyl (12d and
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13d), cyclobutyl (12f and 13f) and cyclopentyl (12e and 13e). The size of the cycle present in position
N8 seems to be extremely important, whilst 3-, 4- and 5-membered rings exhibit the best affinity for
the target kinases.
Concerning the activity against CLK1, comparison of the results obtained for compounds 12a and
12f (IC50 = 0.031 µM and 0.091 µM, respectively) with those obtained for 13a and 13f (IC50 = 0.06 µM
and 0.071 µM, respectively), demonstrates that the presence of methyl or benzyl carbimidates at C2
may have a slightly beneficial effect on the inhibitory activity, accompanied by the same cyclopropyl
substituent on N8. The same phenomenon is observed when data concerning DYRK1A and GSK-3α/β
kinases are compared. The DYRK1A-IC50 values obtained for 12a, 12d–f and 13a, 13d–f series are
mainly in the submicromolar range (0.13 µM < IC50 < 0.39 µM) except for compounds 12a and 13a
(IC50 = 0.091 µM and 0.06 µM, respectively), 12e and 13e (IC50 = 0.072 µM and 0.062 µM, respectively)
and 13f (IC50 = 0.00.59 µM) for which nanomolar IC50 values were observed. These five products show
interesting activity against DYRK1A. As described above for CLK1, the interesting results concern the
fact that two different carbimidate groups gave similar affinity for the same kinase despite changes in
the size of their substituents in position N8. This may suggest the existence of a spatial zone in the
front pocket of the active site of the kinases which is relatively tolerant to various sizes of the molecules
with 3-, 4- or 5- membered cyclolalkyl groups.
In the case of GSK-3α/β, the nanomolar values obtained for compounds 12a, 12d–h and 13a,
13d–h are spectacular and the list of compounds able to show very good affinity for the target kinase
was extended to 12d–13d (IC50 = 0.041 µM and 0.030 µM, respectively) and 12g–13g (IC50 = 0.030 µM
and 0.083 µM, respectively). For GSK-3α/β in particular, the fact that its hydrophobic back-pocket
was recognized to be larger than in the case of the two other kinases (CLK1 and DYRK1A) may explain
why 12d and 12g show very good affinity for this kinase. It may be suggested that the space available
in this back-pocket allowed the molecules to shift and to have a better interaction with GSK-3α/β than
in the other enzymes in which hydrophobic back-pocket are known to have a reduced size. In the
same time the displacement of the tricyclic core into the site may allow the front pocket to be more
tolerant and accept other substituents in N8.
All these results demonstrate that it is difficult to define any role for the various substituents
located at position 8 of the thiazolo[5,4-f ]quinazolin-9(8H)-one. The presence of small-sized cycloalkyl
groups linked to the front pocket is favorable to the development of further SAR studies, whilst the
other side of the molecule (carbimidate function) will perhaps serve to discriminate the pertinent
kinases such as CLK1, DYRK1A and GSK-3α/β (Scheme 5). Although this needs to be confirmed, the
results described in this study indicate clearly that the carbimidate function remains crucial for the
multi-target inhibitory activity of kinases with such heterocyclic structures [13–15].
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The first kinase CLK1 is one of the four isoforms (CLK1-4) of the cdc2-like kinase family.
In humans, the highest levels of CLK1 expression were found in the brain. It was described that
CLK inhibitors may alter the splicing of microtubule-associated protein tau implicated in AD and
Parkinson’s disease [39]. The second kinase targeted by the compounds described in this study is
DYRK1A. Evidence for the role of overexpressed DYRK1A in various neurodegenerative diseases and
Down syndrome is now well established and it has become an attractive drug target for numerous
research groups [40–42]. The third kinase inhibited by the lead molecules in this study was GSK-3α/β
which has definitely gained the attention of research groups and industry. This very versatile kinase
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has become a key target in type II diabetes, bipolar disorder, cancer, chronic inflammatory and immune
disorder and, more importantly, in neurodegenerative diseases, making this enzyme a main target for
AD [43].
Because drugs focusing their activity against a single target may generate low benefits, new
studies are encouraged in the direction of multi-targeting strategies. Therefore, developing molecules
showing submicromolar affinities on a panel of three kinases seems to be of great interest [17]. In this
sense the new thiazolo[5,4-f ]quinazolin-9(8H)-one series described in this paper need to be developed
for the discovery of valuable and pertinent multi-kinases inhibitors.
3. Materials and Methods
3.1. General Information
Starting materials were obtained commercially and used without further purification. All reactions
were monitored by thin-layer chromatography with silica gel 60 F254 precoated aluminium plates
(0.25 mm). Visualization was performed with a UV light at wavelengths of 254 and 312 nm.
Purifications were conducted with a flash column chromatography system equipped with a dual
UV/Vis spectrophotometer (200–600 nm), a fraction collector (176 tubes), a dual piston pump (1 to
200 mL/min, Pmax = 15 bar), which allowed quaternary gradients, and an additional inlet for air
purge. Melting points of solid compounds were measured with a SMP3 Melting Point instrument
(STUART, Bibby Scientific Ltd, Roissy, France) with a precision of ˘1.5 ˝C. IR spectra were recorded
with a Spectrum 100 Series FTIR spectrometer (PerkinElmer, Villebon S/Yvette, France). Liquids
and solids were investigated with a single-reflection attenuated total reflectance (ATR) accessory;
the absorption bands are given in cm´1. NMR spectra (1H and 13C) were acquired at 295 K using a
WP 300 spectrometer an AVANCE 300 MHz spectrometer (Bruker, Wissembourg, France) at 300 and
75.4 MHz, using TMS as an internal standard. Coupling constants J are in Hz, and chemical shifts are
given in ppm. Signals in 13C spectra were assigned based on the result of 13C DEPT135 experiments (see
Supplementary Materials). Mass spectrometry was performed by the Mass Spectrometry Laboratory
of the University of Rouen. The mass spectra [ESI, EI, and field desorption (FD)] were recorded with a
LCP 1er XR spectrometer (WATERS, Guyancourt, France). Microwave experiments were conducted in
a commercial microwave reactor especially designed for synthetic chemistry. Start STM (Milestone S.r.l.,
Bergamo, Italy) is a multi-mode cavity with a microwave power delivery system ranging from 0 to
1200 W. The temperatures of the reactions were mainly monitored via contact-less infrared pyrometer
which was calibrated in control experiments with a fibre-optic contact thermometer protected in a
Teflon coated ceramic well inserted directly in the reaction mixture. Open vessel experiments were
carried out in a 50–250 mL round bottom flask fitted with a reflux condenser. The vessel contents were
stirred by means of an adjustable rotating magnetic plate located below the floor of the microwave
cavity and a Teflon-coated magnetic stir bar inside the vessel. Temperature and power profiles were
monitored in both cases through the EASY-Control software provided by the manufacturer (Milestone
S.r.l., Bergamo, Italy). The times indicated in the various protocols are the times measured when the
mixtures reached the programmed temperature after a ramp period of 2 min.
3.2. Chemistry
3.2.1. General Procedure for the Synthesis of Carbonitriles 11a–n from 10
(E)-Methyl 2-cyano-6-([(dimethylamino)methylene]amino)benzo[d]thiazole-7-carboxylate (10): To a stirred
solution of methyl 6-amino-2-cyanobenzo[d]thiazole-7-carboxylate (1, 1.00 g, 4.29 mmol) in methylene
chloride (20 mL) was added Vilsmeier-Haack reagent (0.824 g, 6.44 mmol, 1.5 equiv) at room
temperature. The resulting mixture was stirred at room temperature for 2 h. On completion, the
crude mixture was diluted with methylene chloride (40 mL) and a saturated aqueous solution of
NaHCO3 (40 mL). After 15 min of stirring, the product was extracted twice with methylene chloride.
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The combined organic layers were washed with brine and dried over MgSO4. Evaporation of solvent
gave the amidine product 10 as a pale yellow solid (1.11 g, 90%), mp. 136–138 ˝C; 1H-NMR (DMSO-d6)
δ 8.23 (d, J = 9.0 Hz, 1H, H4), 7.75 (s, 1H, CH(N)), 7.74 (d, J = 9.0 Hz, 1H, H5), 3.87 (s, 3H, OCH3),
3.10 (s, 3H, NCH3), 3.03 (s, 3H, NCH3); 13C-NMR (DMSO-d6) δ 167.1, 155.8, 154.8, 146.7, 138.3, 135.7,
128.7, 125.4, 114.8, 113.3, 52.3, 34.1; νmax 2952, 2224 (ν C”N), 1622, 1569, 1423, 1331, 1258, 1098, 1016,
831 cm´1; HRMS calcd for C13H13N4O2S [M + H]+ 289.0759 found 289.0746.
In a sealed tube, a suspension of (E)-methyl 2-cyano-6-([(dimethylamino)methylene]-amino)benzo
[d]thiazole-7-carboxylate (10, 125 mg, 0.43 mmol) and the appropriate amine (0.45 mmol, 1.05 equiv)
in acetic acid (600 µL) was irradiated under microwaves at 100 ˝C for 6–10 min. The solvent was
removed under vacuum to provide a crude residue which was purified by flash chromatography on
silica gel with methylene chloride/ethyl acetate (100:0 to 50:50, v/v) as eluent to furnish the expected
8-substituted thiazoloquinazolinone-2-carbonitrile derivatives.
8-Cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11a): white solid (90.0 mg, 78%),
mp. 248–250 ˝C; 1H-NMR (DMSO-d6) δ 8.63 (d, J = 8.7 Hz, 1H, H4), 8.61 (s, 1H, H2), 7.99 (d, J = 9.0 Hz,
1H, H5), 3.42–3.36 (m, 1H, NCH), 1.13–1.09 (m, 4H, CH); 13C-NMR (DMSO-d6) δ 160.2, 150.3, 149.5,
148.2, 139.2, 131.6, 129.9, 127.8, 115.4, 113.5, 29.7, 5.9 (2C); νmax 3067, 2233 (C”N), 1664, 1579, 1441,
1353, 1303, 1222, 1038, 839, 692 cm´1; HRMS calcd for C13H9N4OS [M + H]+ 269.0497 found 269.0487.
8-(2-Methoxyethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11b): pale beige solid
(100.8 mg, 82%), mp. 204–206 ˝C; 1H-NMR (CDCl3) δ 8.67 (d, J = 9.0 Hz, 1H, H4), 8.62 (s, 1H,
H2), 8.02 (d, J = 9.0 Hz, 1H, H5), 4.32 (t, J = 5.1 Hz, 2H, OCH2), 3.69 (t, J = 5.1 Hz, 2H, NCH2), 3.26
(s, 3H, OCH3); 13C-NMR (DMSO-d6) δ 159.9, 150.3, 149.8, 148.7, 139.2, 131.7, 130.1, 127.9, 115.4, 113.5,
68.8, 58.1, 46.0; νmax 3098, 2932, 2891, 2237 (ν C”N), 1656, 1582, 1352, 1111, 1013, 835, 559 cm´1; HRMS
calcd for C13H11N4O2S [M + H]+ 287.0603 found 287.0605.
8-(3-Methoxypropyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11c): pale beige solid
(103.4 mg, 80%), mp. 128–130 ˝C; 1H-NMR (DMSO-d6) δ 8.68 (s, 1H, H7), 8.65 (d, J = 9.0 Hz, 1H, H4),
8.01 (d, J = 9.0 Hz, 1H, H5), 4.19 (t, J = 6.9 Hz, 2H, OCH2), 3.41 (t, J = 6.0 Hz, 2H, NCH2), 3.21 (s, 3H,
OMe), 2.01 (dt, J = 6.9, 6.0 Hz, 2H, CH2); 13C-NMR (DMSO-d6) δ 159.0, 150.3, 149.6, 148.7, 139.2, 131.7,
129.9, 127.9, 115.5, 113.6, 69.1, 57.9, 44.6, 28.2; νmax 3058, 2901, 2878, 2831, 2232 (ν C”N), 1656, 1586,
1470, 1354, 1156, 1110, 889, 847 cm´1; HRMS calcd for C14H13N4O2S [M + H]+ 301.0759 found 301.075.
8-(3-Isopropyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11d): obtained in 58% yield as a
white solid (mp > 265 ˝C). Data supporting its chemical structure are reported in [6].
8-Cyclopentyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11e): beige solid (89.2 mg, 70%),
mp > 265˝C; 1H-NMR (DMSO-d6) δ 8.75 (s, 1H, H2), 8.66 (d, J = 8.7 Hz, 1H, H4), 8.02 (d, J = 8.7 Hz,
1H, H5), 5.13–5.06 (m, 1H, NCH), 2.22–1.61 (m, 8H, CH); 13C-NMR (CDCl3 + DMSO-d6) δ 159.0, 150.4,
147.3, 139.2, 129.8, 127.8, 113.7, 57.2, 30.0, 24.1; νmax 3074, 2961, 2233 (ν C”N), 1657, 1583, 1473, 1356,
1254, 1105, 840 cm´1; HRMS calcd for C15H13N4OS [M + H]+ 297.0810 found 297.0820.
8-Cyclobutyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11f): white solid (88.5 mg, 73%),
mp > 265 ˝C; 1H-NMR (CDCl3) δ 8.52 (d, J = 8.7 Hz, 1H, H4), 8.40 (s, 1H, H2), 7.98 (d, J = 8.7 Hz, 1H,
H5), 5.21–5.09 (m, 1H, NCH), 2.71–2.61 (m, 2H, CH), 2.54–2.40 (m, 2H, CH), 2.07–2.02 (m, 2H, CH);
13C-NMR (DMSO-d6) δ 159.7, 151.6, 148.8, 145.2, 140.3, 132.4, 130.6, 128.2, 116.1, 113.4, 51.2, 30.0 (2C),
15.6; νmax 3441, 3296, 3092, 2233 (ν C”N), 1662, 1586, 1280, 1145, 1059, 1114, 841 cm´1; HRMS calcd
for C14H11N4OS [M + H]+ 283.0654 found 283.0660.
8-Cyclohexyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11g): white solid (92.4 mg, 69%),
mp. 256–258 ˝C; 1H-NMR (DMSO-d6) δ 8.81 (s, 1H, H7), 8.65 (d, J = 9.0 Hz, 1H, H4), 8.01 (d, J = 9.0 Hz,
1H, H5), 4.78–4.71 (m, 1H, NCH), 2.0–1.21 (m, 10H, CH); 13C-NMR (DMSO-d6) δ 158.6, 150.3, 148.1,
147.2, 139.2, 131.9, 130.0, 127.9, 115.4, 113.6, 54.7, 31.1 (2C), 25.5 (2C), 24.6; νmax 3060, 2940, 2869,
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2226 (ν C”N), 1657, 1583, 1466, 1448, 1388, 1346, 1183, 1127, 830 cm´1; HRMS calcd for C16H15N4OS
[M + H]+ 311.0967 found 311.0966.
8-Dimethylamino-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11h): beige solid (98.0 mg,
84%), mp > 265 ˝C; 1H-NMR (DMSO-d6) δ 8.68 (d, J = 8.8 Hz, 1H, H4), 8.61 (s, 1H, H2), 8.03 (d,
J = 8.8 Hz, 1H, H5), 3.10 (s, 6H, CH3); 13C-NMR (DMSO-d6) δ 159.0, 150.9, 150.3, 148.1, 139.4, 131.5,
130.1, 128.0, 117.1, 113.5, 44.2 (2C); νmax 3080, 2966, 2887, 2231 (C”N), 1659, 1577, 1442, 1349, 1299,
1156, 1060, 839, 696 cm´1; HRMS calcd for C12H10N5OS [M + H]+ 272.0606 found 272.0600.
8-(2-Dimethylaminoethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11i): white solid
(99.1 mg, 77%), mp > 265 ˝C; 1H-NMR (CDCl3) δ 8.52 (d, J = 9.0 Hz, 1H, H4), 8.30 (s, 1H, H7),
7.98 (d, J = 9.0 Hz, 1H, H5), 4.22 (t, J = 6.0 Hz, 2H, NCH2), 2.72 (t, J = 6.0 Hz, 2H, NCH2), 2.30 (s, 6H,
NCH3); 13C-NMR (CDCl3) δ 159.5, 151.3, 149.0, 148.3, 140.0, 132.3, 130.3, 128.1, 116.2, 113.2, 57.7, 45.0;
νmax 3072, 2949, 2826, 2781, 2235 (ν C”N), 1667, 1585, 1465, 1354, 1151, 931, 832 cm´1; HRMS calcd for
C14H14N5O2S [M + OH]´ 316.0868 found 316.0872.
8-(2-Dimethylaminoethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11j): yellow solid
(114.5 mg, 78%), mp. 192–194 ˝C; 1H-NMR (CDCl3) δ 8.52 (d, J = 9.0 Hz, 1H, H4), 8.28 (s, 1H,
H7), 7.97 (d, J = 9.0 Hz, 1H, H5), 4.23 (t, J = 5.7 Hz, 2H, NCH2), 3.68–3.65 (m, 4H, CH), 2.77 (t, J = 5.7 Hz,
2H, NCH2), 2.54–2.51 (m, 4H, CH); 13C-NMR (CDCl3) δ 159.7, 151.5, 149.2, 148.4, 140.3, 132.5, 130.6,
128.3, 116.3, 113.4, 67.1 (2C), 57.0, 53.9 (2C), 44.0; νmax 3060, 2925, 2815, 1659, 1586, 1452, 1345, 1112,
833 cm´1; HRMS calcd for C16H16N5O2S [M + H]+ 342.1025 found 342.1026.
8-(p-Tolyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11k): white solid (116.4 mg, 85%),
mp > 265 ˝C; 1H-NMR (DMSO-d6) δ 8.72 (d, J = 9.0 Hz, 1H, H4), 8.67 (s, 1H, H2), 8.09 (d, J = 9.0 Hz,
1H, H5), 7.51 (d, J = 8.4 Hz, 2H, HAr), 7.42 (d, J = 8.4 Hz, 2H, HAr), 2.43 (s, 3H, CH3); νmax 3057, 2225
(ν C”N), 1668, 1580, 1490, 1353, 1273, 1189, 1091, 847, 835, 802, 576 cm´1.
8-(4-Methoxyphenyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11l): white solid (33.7 mg,
46%), mp > 265 ˝C; 1H-NMR (DMSO-d6) δ 8.71 (d, J = 8.7 Hz, 1H, H4), 8.66 (s, 1H, H2), 8.08 (d,
J = 8.7 Hz, 1H, H5), 7.56 (d, J = 9.0 Hz, 2H, ArH), 7.15 (d, J = 9.0 Hz, 2H, ArH), 3.56 (s, 3H, OCH3);
νmax 3099, 2932, 2237 (ν C”N), 1656, 1584, 1352, 1111, 1013, 835 cm´1; HRMS calcd for C17H11N4O3S
[M+OH]´ 351.0552 found 351.0548.
8-(4-Dimethylaminophenyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11m): yellow solid
(121.0 mg, 81%), mp. 224–226 ˝C; 1H-NMR (DMSO-d6) δ 8.70 (d, J = 9.0 Hz, 1H, H4), 8.63 (s, 1H, H2),
8.07 (d, J = 9.0 Hz, 1H, H5), 7.40 (d, J = 9.0 Hz, 2H, ArH), 6.87 (d, J = 9.0 Hz, 2H, ArH), 2.99 (s, 6H,
NCH3); νmax 3374, 3061, 2234 (ν C”N), 1661, 1611, 14583, 1518, 1353, 1277, 1189, 836, 805 cm´1; HRMS
calcd for C18H14N5O2S [M + OH]´ 364.0868 found 364.0872.
8-Methyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbonitrile (11n): white solid (87.5 mg, 84%), mp.
248–250 ˝C; 1H-NMR (CDCl3) δ 8.53 (d, J = 9.0 Hz, 1H, H4), 8.30 (s, 1H, H2), 7.98 (d, J = 9.0 Hz, 1H,
H5), 3.77 (s, 3H, NCH3); 13C-NMR (CDCl3) δ 160.0, 151.5, 149.2, 147.9, 140.3, 132.2, 130.5, 128.2, 116.2,
113.3, 34.5; νmax 2987, 2904, 2234 (ν C”N), 1664, 1669, 1588, 1357, 1334, 1055, 841 cm´1; HRMS calcd
for C11H7N4OS [M + H]+ 243.0341 found 243.0334.
3.2.2. General Procedure for the Synthesis of Carbimidates 12a–n, 13a–h, 14a–e and 15a–c from 11a–n
To a stirred solution of 11a–n (0.25 mmol, 1 equiv) in appropriate alcohol (2.5 mL) was added
an aqueous solution of sodium hydroxyde (2.5 M, 100 µL, 1.0 equiv) and the resulting mixture
was stirred at room temperature for 1 h under argon atmosphere. The solvent was removed under
vacuum and the crude residue was adsorbed on Celite® and purified by flash chromatography on
silica gel with methylene chloride/methanol (100:0 to 2:98; v/v) as eluent to furnish the desired
carbimidate compound.
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Ethyl 8-cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f ]quinazoline-2-carbimidates 12a–n
Methyl 8-cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12a): white solid (68 mg,
91%), mp. 234–236 ˝C; 1H-NMR (CDCl3) δ 8.94 (s, 1H, NH), 8.40 (d, J = 9.0 Hz, 1H, H4), 8.22 (s, 1H,
H7), 7.78 (d, J = 9.0 Hz, 1H, H5), 4.04 (s, 3H, OCH3), 3.37–3.29 (m, 1H, NCH), 1.27–1.23 (m, 2H, CH),
1.01–1.00 (m, 2H, CH); 13C-NMR (CDCl3) δ 161.9 (2C), 160.9, 151.8, 147.2, 147.0, 133.0, 129.8, 126.7,
116.3, 54.4, 29.7, 6.6 (2C); νmax 3272, 2918, 2848, 1728, 1664, 1583, 1498, 1438, 1339, 1141, 1060, 893,
837 cm´1; HRMS calcd for C14H13N4O2S [M + H]+ 301.0759 found 301.0771.
Methyl 8-(2-methoxyethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12b): white solid
(56.5 mg, 71%), mp. 196–198 ˝C; 1H-NMR (DMSO-d6) δ 9.46 (s, 1H, NH), 8.57 (d, J = 8.7 Hz, 1H,
H4), 8.54 (s, 1H, H7), 7.93 (d, J = 8.7 Hz, 1H, H5), 4.31 (t, J = 5.1 Hz, 2H, OCH2), 3.98 (s, 1H, OCH3),
3.68 (t, J = 5.1 Hz, 2H, NCH2), 3.26 (s, 3H, OCH3); 13C-NMR (DMSO-d6) δ 160.6, 159.9, 159.0, 150.9,
149.0, 147.6, 131.7, 129.6, 126.9, 115.9, 68.9, 58.1, 54.1, 45.9; νmax 3271, 2914, 1651, 1587, 1444, 1340, 1111,
1065 cm´1; HRMS calcd for C14H15N4O2S [M + H]+ 319.0865 found 319.0880.
Methyl 8-(3-methoxypropyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12c): white solid
(63.0 mg, 76%), mp. 168–170 ˝C; 1H-NMR (DMSO-d6) δ 9.45 (s, 1H, NH), 8.59 (s, 1H, H7), 8.54 (d,
J = 8.7 Hz, 1H, H4), 7.91 (d, J = 8.7 Hz, 1H, H5), 4.16 (t, J = 6.2 Hz, 2H, NCH2), 3.98 (s, 3H, OCH3), 3.40
(t, J = 5.7 Hz, 2H, OCH2), 3.22 (s, 3H, OCH3), 2.00 (dt, J = 6.2, 5.7 Hz, 2H, CH2); 13C-NMR (DMSO-d6) δ
160.6, 160.0, 159.0, 150.8, 148.7, 147.6, 131.6, 129.4, 126.8, 115.9, 69.1, 57.9, 54.0, 44.4, 28.2; νmax 3272,
2946, 1658, 1635, 1588, 1350, 1105, 889, 831 cm´1; HRMS calcd for C15H17N4O3S [M + H]+ 333.1021
found 333.1030.
Methyl 8-isopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12d): white solid (69.5 mg,
92%), mp. 234–236 ˝C; 1H-NMR (DMSO-d6) δ 9.45 (s, 1H, NH), 8.73 (s, 1H, H7), 8.55 (d, J = 9.0 Hz,
1H, H4), 7.93 (d, J = 9.0 Hz, 1H, H5), 5.15–5.08 (sept, J = 6.9 Hz, 1H, NCH), 3.99 (s, 3H, OCH3), 1.50 (d,
J = 6.9 Hz, 6H, CH3); 13C-NMR (DMSO-d6) δ 160.6, 160.0, 158.7, 150.8, 147.1, 146.1, 131.9, 129.5, 126.8,
115.8, 54.0, 47.0, 21.2 (2C); νmax 3315, 3061, 2977, 1673, 1657, 1583, 1347, 1072, 838, 699 cm´1; HRMS
calcd for C14H15N4O2S [M + H]+ 303.0916 found 303.0919.
Methyl 8-cyclopentyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12e): white solid (73 mg,
89%), mp. 226–228 ˝C; 1H-NMR (DMSO-d6) δ 9.45 (s, 1H, NH), 8.66 (s, 1H, H7), 8.55 (d, J = 8.7 Hz, 1H,
H4), 7.91 (d, J = 8.7 Hz, 1H, H5), 5.13–5.05 (m, 1H, NCH), 3.98 (s, 3H, OCH3), 2.22–2.09 (m, 2H, CH),
2.04–1.87 (m, 4H, CH), 1.77–1.65 (m, 2H, CH); 13C-NMR (DMSO-d6) δ 160.7, 160.0, 159.1, 150.9, 147.1,
146.6, 131.9, 129.5, 126.8, 115.8, 56.6, 54.1, 31.0 (2C), 24.1 (2C); νmax 3293, 2933, 2862, 1657, 1636, 1579,
1494, 1434, 1349, 1254, 840 cm´1; HRMS calcd for C16H17N4O2S [M + H]+ 329.1072 found 329.1077.
Methyl 8-cyclobutyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12f): white solid (59.7 mg,
76%), mp. 260–262 ˝C; 1H-NMR (DMSO-d6) δ 9.46 (s, 1H, NH), 8.72 (s, 1H, H7), 8.56 (d, J = 8.7 Hz, 1H,
H4), 7.93 (d, J = 8.7 Hz, 1H, H5), 5.15–5.07 (m, 1H, NCH), 3.99 (s, 3H, OCH3), 1.90–1.85 (m, 4H, CH),
1.23–1.18 (m, 2H, CH); 13C-NMR (DMSO-d6) δ 162.0 (2C), 159.8, 151.9, 147.5, 144.3, 133.2, 129.9, 126.8,
116.5, 54.5, 50.9, 29.9 (2C), 15.5; νmax 3296, 2983, 2955, 1661, 1636, 1580, 1494, 1436, 1351, 1255, 1155,
841 cm´1; HRMS calcd for C15H15N4O2S [M + H]+ 315.0916 found 315.0918.
Methyl 8-cyclohexyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12g): white powder (78 mg,
92%), mp. 246–248 ˝C; 1H-NMR (DMSO-d6) δ 9.45 (s, 1H, NH), 8.73 (s, 1H, H7), 8.56 (d, J = 8.7 Hz,
1H, H4), 7.93 (d, J = 8.7 Hz, 1H, H5), 4.79–4.72 (m, 1H, NCH), 3.99 (s, 3H, OCH3), 1.97–1.38 (m, 10,
CH); 13C-NMR (DMSO-d6) δ 162.0, 161.9, 159.5, 151.8, 147.3, 144.2, 133.4, 129.9, 126.7, 116.6, 54.5, 32.7
(2C), 26.0 (2C), 35.3; νmax 3298, 2946, 2856, 1658, 1586, 1333, 1139, 1078, 834 cm´1; HRMS calcd for
C17H19N4O2S [M + H]+ 343.1229 found 343.1224.
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Methyl 8-dimethylamino-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12h): white solid
(53.1 mg, 70%), mp. 246–248 ˝C; 1H-NMR (DMSO-d6) δ 9.46 (s, 1H, NH), 8.57 (d, J = 9.0 Hz, 1H,
H4), 8.52 (s, 1H, H7), 7.94 (d, J = 9.0 Hz, 1H, H5), 3.99 (s, 3H, OCH3), 3.10 (s, 6H, NCH3); 13C-NMR
(CDCl3) δ 162.1, 162.0, 160.0, 151.9, 149.3, 147.4, 133.0, 130.0, 127.0, 118.1, 54.5, 45.0 (2C); νmax 3299, 3073,
3036, 2945, 1670, 1637, 1580, 1437, 1347, 1158, 1079, 838, 808, 706 cm´1; HRMS calcd for C13H14N5O2S
[M + H]+ 304.0868 found 304.0871.
Methyl 8-[(3-dimethylamino)ethyl]-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12i): white
solid (66.3 mg, 80%), mp. 178–180 ˝C; 1H-NMR (DMSO-d6) δ 9.46 (s, 1H, NH), 8.57 (s, 1H, H7), 8.56 (d,
J = 9.0 Hz, 1H, H4), 7.92 (d, J = 9.0 Hz, 1H, H5), 4.21 (t, J = 6.0 Hz, 2H, NCH2), 3.98 (s, 3H, OCH3), 2.61
(t, J = 6.0 Hz, 2H, NCH2), 2.20 (s, 6H, NCH3); 13C-NMR (DMSO-d6) δ 158.9, 150.3, 149.7, 148.7, 139.1,
131.7, 130.0, 127.9, 115.4, 113.5, 57.0, 45.2 (2C), 44.0, 30.7; νmax 3201, 2981, 2774, 1650, 1587, 1442, 1341,
1066, 826 cm´1; HRMS calcd for C15H18N5O2S [M + H]+ 332.1181 found 332.1178.
Methyl 8-(2-morpholinoethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12j): light yellow
solid (80.3 mg, 86%), mp. 190–192 ˝C; 1H-NMR (DMSO-d6) δ 9.41 (s, 1H, NH), 8.56 (s, 1H, H7), 8.52
(d, J = 9.0 Hz, 1H, H4), 7.92 (d, J = 9.0 Hz, 1H, H5), 4.22 (t, J = 6.0 Hz, 2H, NCH2), 3.98 (s, 3H, OCH3),
3.54–3.51 (m, 4H, OCH2), 2.67 (t, J = 6.0 Hz, 2H, NCH2), 2.48–2.46 (m, 4H, NCH2); 13C-NMR (DMSO-d6)
δ 160.6, 160.0, 159.0, 150.8, 148.9, 147.6, 131.7, 129.5, 126.8, 115.8, 115.8, 66.2 (2C), 56.2, 54.0, 53.1 (2C),
42.9; νmax 3452, 3296, 2944, 2804, 1649, 1587, 1497, 1439, 1340, 1065, 1112, 1065, 825 cm´1; HRMS calcd
for C17H20N5O3S [M + H]+ 374.1287 found 374.1278.
Methyl 8-(p-tolyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12k): white solid (59.0 mg,
68%), mp > 265 ˝C; 1H-NMR (DMSO-d6) δ 9.47 (s, 1H, NH), 8.55 (d, J = 8.7 Hz, 1H, H5), 8.57 (s, 1H,
H7), 7.99 (d, J = 8.7 Hz, 1H, H4), 7.51 (d, J = 8.4 Hz, 2H, HAr), 7.42 (d, J = 8.4 Hz, 2H, HAr), 3.97 (s, 3H,
OCH3), 2.42 (s, 3H, CH3); νmax 3257, 3060, 1644, 1576, 1490, 1320, 1263, 1185.0, 803, 781 cm´1; HRMS
calcd for C18H15N4O2S [M + H]+ 351,0916 found 351.0950.
Methyl 8-(4-methoxyphenyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12l): white solid
(74.6 mg, 82%), mp > 265 ˝C; 1H-NMR (DMSO-d6) δ 9.47 (s, 1H, NH), 8.61 (d, J = 8.7 Hz, 1H, H4), 8.57
(s, 1H, H7), 7.99 (d, J = 8.7 Hz, 1H, H5), 7.55 (d, J = 9.0 Hz, 2H, HAr), 7.15 (d, J = 9.0 Hz, 2H, ArH), 3.98
(s, 3H, OCH3), 3.86 (s, 3H, OCH3); νmax 3307, 3061, 1671, 1582, 1516, 1339, 1261, 832 cm´1; HRMS calcd
for C18H15N4O3S [M + H]+ 367.0865 found 367.0873.
Methyl 8-(4-dimethylaminophenyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12m): yellow
solid (70.2 mg, 74%), mp > 265 ˝C; 1H-NMR (DMSO-d6) δ 9.46 (s, 1H, NH), 8.60 (d, J = 8.7 Hz, 1H, H4),
8.54 (s, 1H, H7), 7.98 (d, J = 8.7 Hz, 1H, H5), 7.38 (d, J = 9.0 Hz, 2H, HAr), 6.86 (d, J = 9.0 Hz, 2H, HAr),
3.98 (s, 3H, OCH3), 2.99 (s, 6H, NCH3); νmax 3245, 2932, 2854, 1659, 1587, 1347, 1192, 836, 805 cm´1;
HRMS calcd for C19H18N5O2S [M + H]+ 380.1181 found 380.1196.
Methyl 8-methyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (12n): white solid (61.7 mg, 90%),
mp. 244–246 ˝C; 1H-NMR (DMSO-d6) δ 9.44 (s, 1H, NH), 8.62 (s, 1H, H7), 8.54 (d, J = 8.7 Hz, 1H, H4),
7.91 (d, J = 8.7 Hz, 1H, H5), 3.98 (s, 3H, OCH3), 3.32 (s, 3H, NCH3); 13C-NMR (DMSO-d6) δ 160.6, 160.0,
159.5, 150.8, 149.1, 147.8, 135.4, 131.6, 129.4, 126.9, 115.8, 54.0, 33.9; νmax 3257, 2949, 1655, 1589, 1436,
1339, 1153, 1064, 839, 716, 498 cm´1; HRMS calcd for C12H11N4O2S [M + H]+ 275.0603 found 275.0608.
Benzyl 8-cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f ]quinazoline-2-carbimidates (13a–h)
Benzyl 8-cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (13a): white solid (48 mg,
85%), mp. 214–216 ˝C; 1H-NMR (CDCl3) δ 9.60 (s, 1H, NH), 8.56 (d, J = 9.0 Hz, 1H, H4), 8.53 (s, 1H,
H7), 7.92 (d, J = 9.0 Hz, 1H, H5), 7.57–7.40 (m, 5H, Ph), 5.48 (s, 2H, CH2Ph), 3.30–3.15 (m, 1H, CH),
1.11–1.06 (m, 4H, CH); 13C-NMR (CDCl3) δ 162.1, 161.2, 161.1, 152.0, 147.4, 147.1, 136.0, 133.3, 130.0,
128.7 (2C), 128.3, 127.9 (2C), 126.9, 116.5, 68.8, 29.8, 6.7 (2C); νmax 3286, 3024, 1660, 1636, 1586, 1491,
1335, 1155, 1084, 833, 734 cm´1; HRMS calcd for C20H17N4O2S [M + H]+ 377.1072 found 377.1082.
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Benzyl 8-(2-methoxyethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (13b): white solid
(57.1 mg, 58%), mp. 160–162˝C; 1H-NMR (DMSO-d6) δ 9.61 (s, 1H, NH), 8.58 (d, J = 9.0 Hz, 1H,
H4), 8.54 (s, 1H, H7), 7.93 (d, J = 9.0 Hz, 1H, H5), 7.56–7.38 (m, 5H, Ph), 5.47 (s, 2H, CH2Ph), 4.29 (t,
J = 5.1 Hz, 2H, OCH2), 3.67 (t, J = 5.1 Hz, 2H, NCH2), 3.26 (s, 3H, OCH3); 13C-NMR (DMSO-d6) δ
160.7, 159.1, 159.0, 151.0, 149.0, 147.6, 136.3 ,131.7, 129.7, 128.5 (2C), 128.0, 127.8 (2C), 126.9, 115.9, 69.1,
67.8, 58.1, 45.9; νmax 3456, 3396, 3275, 2925, 1656, 1589, 1334, 1105, 1005, 837 cm´1; HRMS calcd for
C20H19N4O3S [M + H]+ 395.1178 found 395.1177.
Benzyl 8-(3-methoxypropyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (13c): white solid
(56.2 mg, 55%), mp. 168–170 ˝C; 1H-NMR (DMSO-d6) δ 9.60 (s, 1H, NH), 8.59 (s, 1H, H7), 8.57 (d,
J = 9.0 Hz, 1H, H4), 7.93 (d, J = 9.0 Hz, 1H, H5), 7.56–7.39 (m, 5H, Ph), 5.47 (s, 1H, CH2Ph), 4.16 (t,
J = 6.9 Hz, 2H, NCH2), 3.40 (t, J = 6.0 Hz, 2H, OCH2), 3.21 (s, 3H, OCH3), 2.00 (dt, J = 6.9, 6.0 Hz, 2H,
CH2); 13C-NMR (DMSO-d6) δ 160.7, 159.2, 159.1, 150.9, 148.7, 147.7, 136.3 ,131.7, 129.5, 128.4 (2C), 128.0,
127.8 (2C), 126.9, 116.0, 69.1, 67.8, 57.9, 44.4, 28.2; νmax 3272, 3078, 2923, 2865, 1666, 1647, 1584, 1453,
1317, 1113, 1050, 890, 837, 749 cm´1; HRMS calcd for C21H21N4O3S [M + H]+ 409.1334 found 409.1333.
Benzyl 8-isopropyl-9-oxo-8,9-dihydro[1,3]thiazolo[5,4-f]quinazoline-2-carbimidate (13d): white solid (61 mg,
65%), mp. 212–214 ˝C; 1H-NMR (DMSO-d6) δ 9.60 (s, 1H, NH), 8.72 (s, 1H, H7), 8.56 (d, J = 8.7 Hz, 1H,
H4), 7.93 (d, J = 8.7 Hz, 1H, H5), 7.56–7.38 (m, 5H, Ph), 5.47 (s, 2H, CH2Ph), 5.02–5.11 (sept, J = 6.9 Hz,
1H, NCH), 1.50 (d, J = 6.9 Hz, 6H, CH3). Other data supporting its chemical structure are reported
in [6].
Benzyl 8-cyclopentyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (13e): white solid (91 mg,
90%), mp. 214–216 ˝C; 1H-NMR (DMSO-d6) δ 9.58 (s, 1H, NH), 8.65 (s, 1H, H7), 8.55 (d, J = 8.7 Hz, 1H,
H4), 7.92 (d, J = 8.7 Hz, 1H, H5), 7.57–7.39 (m, 5H, Ph), 5.47 (s, 2H, CH2Ph), 5.13–5.02 (m, 1H, NCH),
2.21–2.09 (m, 2H, CH2), 2.00–1.87 (m, 4H, 2 ˆ CH2), 1.79–1.60 (m, 2H, CH2); 13C-NMR (DMSO-d6) δ
161.9, 161.3, 160.0, 151.9, 147.4, 144.7, 136.0, 133.4, 129.9, 128.7 (2C), 128.3, 128.0 (2C), 126.8, 116.6, 68.8,
57.0, 32.2 (2C), 24.6 (2C); νmax 3300, 2926, 2869, 1671, 1660, 1632, 1583, 1491, 1335, 1318, 1257, 1144, 830,
745 cm´1; HRMS calcd for C22H21N4O2S [M + H]+ 405.1385 found 405.1394.
Benzyl 8-cyclobutyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (13f): white solid (84 mg,
86%), mp. 234–236 ˝C; 1H-NMR (CDCl3) δ 9.11 (s, 1H, NH), 8.44 (d, J = 8.7 Hz, 1H, H4), 8.32 (s, 1H,
H7), 7.89 (d, J = 8.7 Hz, 1H, H5), 7.53–7.36 (m, 5H, Ph), 5.50 (s, 2H, CH2Ph), 5.16–5.04 (m, 1H, NCH),
2.63 (m, 2H, 2 ˆ CH), 2.52–2.43 (m, 2H,2 ˆ CH), 2.02–2.00 (m, 2H, 2 x CH); 13C-NMR (CDCl3) δ 161.9,
161.3, 159.9, 152.0, 147.6, 144.3, 136.0, 133.3, 130.0, 128.7 (2C), 128.3, 128.0 (2C), 126.9, 116.5, 68.9, 51.2,
29.8 (2C), 15.6; νmax 3301, 3055, 2983, 2955, 2921, 1659, 1640, 1581, 1340, 1159, 830, 733 cm´1; HRMS
calcd for C21H19N4O2S [M + H]+ 391.1229 found 391.1216.
Benzyl 8-cyclohexyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (13g): white solid (59 mg,
94%), mp. 212–214 ˝C; 1H-NMR (CDCl3) δ 9.11 (s, 1H, NH), 8.42 (d, J = 8.7 Hz, 1H, H4), 8.27 (s, 1H,
H7), 7.85 (d, J = 8.7 Hz, 1H, H5), 7.52–7.34 (m, 5H, Ph), 5.50 (s, 2H, CH2Ph), 4.89–4.81 (m, 1H, NCH),
2.08-1.25 (m, 10H, 5 ˆ CH2); 13C-NMR (CDCl3) δ 162.0, 161.4, 159.7, 152.0, 147.4, 144.3, 136.2, 133.6,
130.0, 128.8, 128.3, 127.9, 126.9, 68.9, 54.9, 32.8, 26.1, 25.4; νmax 3301, 2931, 2861, 1656, 1627, 1583, 1490,
1334, 1146, 1078, 833, 744, 700 cm´1; HRMS calcd for C23H23N4O2S [M + H]+ 419.1542 found 419.1546.
Benzyl 8-dimethylamino-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (13h): white solid (45 mg,
80%), mp. 190–192 ˝C; 1H-NMR (DMSO-d6) δ 9.61 (s, 1H, NH), 8.58 (d, J = 9.0 Hz, 1H, H4), 8.52 (s,
1H, H7), 7.94 (d, J = 9.0 Hz, 1H, H5), 7.57–7.37 (m, 5H, Ph), 5.48 (s, 2H, CH2Ph), 3.09 (s, 6H, 2 ˆ CH3);
13C-NMR (DMSO-d6) δ 161.1, 159.1, 151.0, 150.0, 147.0, 138.3, 129.7, 128.5 (2C), 128.1, 127.9 (2C), 117.6,
67.9, 44.2 (2C); νmax 3291, 3038, 2922, 1688, 1642, 1578, 1493, 1444, 1330, 1295, 1164, 1072, 916, 827, 752,
699 cm´1; HRMS calcd for C19H18N5O2S [M + H]+ 380.1181 found 380.1183.
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Ethyl 9-oxo-8,9-dihydrothiazolo[5,4-f ]quinazoline-2-carbimidates (14a–e)
Ethyl 8-cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (14a): white solid (73.0 mg,
93%), mp. 248–250 ˝C; 1H-NMR (CDCl3) δ 8.94 (s, 1H, NH), 8.42 (d, J = 9.0. Hz, 1H, H4), 8.27 (s,
1H, H7), 7.86 (d, J = 9.0 Hz, 1H, H5), 4.49 (q, J = 7.2 Hz, 2H, OCH2), 3.41–3.33 (m, 1H, NCH), 1.48 (t,
J = 7.2 Hz, 3H, CH3), 1.33–1.24 (m, 2H, CH), 1.06–1.03 (m, 2H, CH); 13C-NMR (CDCl3) δ 162.6, 161.4,
161.1, 152.0, 147.3, 147.1, 133.2, 130.0, 126.8, 116.5, 63.2, 29.7, 14.3, 6.7 (2C); νmax 3279, 2982, 1666,
1633, 1584, 1497, 1345, 1274, 1076, 866, 845 cm´1; HRMS calcd for C15H15N4O2S [M + H]+ 315.0916
found 315.0901.
Ethyl 8-(2-methoxyethyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carboximidoate (14b): white solid
(63.2 mg, 76%), mp. 166–168 ˝C, 1H-NMR (DMSO-d6) δ 9.36 (br s, 1H, NH), 8.54 (d, J = 9.0 Hz, 1H,
H4), 8.53 (s, 1H, H7), 7.90 (d, J = 9.0 Hz, 1H, H5), 4.42 (q, J = 7.2 Hz, 2H, OCH2), 4.30 (t, J = 5.1 Hz,
2H, OCH2), 3.68 (t, J = 5.1 Hz, 2H, NCH2), 3.27 (s, 3H, OCH3), 1.41 (t, J = 7.2 Hz, 3H, CH3); νmax 3308,
3160, 2985, 1663, 1589, 1347, 1112, 1005, 837 cm´1; HRMS calcd for C15H17N4O3S [M + H]+ 333.1021
found 333.1023.
Ethyl 8-(3-methoxypropyl)-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carboximidoate (14c): white solid
(62 mg, 72%), mp. 172–174 ˝C; 1H-NMR (DMSO-d6) δ 9.37 (s, 1H, NH), 8.59 (s, 1H, H7), 8.55 (d,
J = 8.9 Hz, 1H, H4), 7.91 (d, J = 8.9 Hz, 1H, H5), 4.42 (q, J = 7.2 Hz, 1H, CH2), 4.17 (t, J = 6.9 Hz, 2H,
OCH2), 3.40 (t, J = 6.0 Hz, 2H, NCH2), 3.32 (s, 3H, OCH3), 2.00 (dt, J = 6.9, 6.0 Hz, 2H, CH2), 1.41 (t,
J = 7.2 Hz, 3H, CH3); 13C-NMR (DMSO-d6) δ 160.9, 159.4, 159.1, 150.9, 148.7, 147.6, 131.7, 129.5, 126.8,
116.0, 69.1, 62.5, 57.9, 44.4, 28.2, 14.0; νmax 3280, 2973, 2867, 1660, 1640, 1581, 1327, 1107, 893, 827 cm´1;
HRMS calcd for C16H19N4O3S [M + H]+ 347.1173, found 347.1178.
Ethyl 8-isopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carboximidoate (14d): white solid (63.3.mg,
80%), mp. 196–198 ˝C; 1H-NMR (DMSO-d6) δ 9.37 (s, 1H, NH), 8.72 (s, 1H, H7), 8.55 (d, 8.7 Hz, 1H,
H4), 7.92 (d, 8.7 Hz, 1H, H5), 5.13–5.04 (m, 1H, NCH), 4.42 (q, J = 6.9 Hz, 2H, OCH2), 1.50 (d, J = 6.9 Hz,
6H, 2x CH3), 1.42 (t, 7.2 Hz, 1H, CH3). Other data supporting its chemical structure are reported in [6].
Ethyl 8-cyclopentyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (14e): white solid (79 mg,
92%), mp. 218-220 ˝C; 1H-NMR (CDCl3) δ 8.94 (s, 1H, NH), 8.41 (d, J = 9.0 Hz, 1H, H4), 8.27 (s, 1H, H7),
7.86 (d, J = 9.0 Hz, 1H, H5), 5.22 (m, 1H, NCH), 4.49 (q, J = 6.9 Hz, 2H, OCH2), 2.27 (m, 2H, CH), 1.95
(m, 6H, CH), 1.48 (t, J = 6.9 Hz, 3H, CH3); 13C-NMR (CDCl3) δ 162.3, 161.4, 159.8, 151.8, 147.2, 144.6,
133.2, 129.8, 126.6, 116.5, 63.1, 56.9, 32.1 (2C), 24.6 (2C), 14.2; νmax 3274, 3063, 2922, 1647, 1587, 1495,
1323, 21143, 1118, 1055, 836 cm´1; HRMS calcd for C17H19N4O2S [M + H]+ 343.1229 found 343.1232.
Isopropyl 9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidates 15a–c
Isopropyl 8-cyclopropyl-9-oxo-8,9-dihydrothiazolo[5,4-f]quinazoline-2-carbimidate (15a): white solid (72.2 mg,
88%), mp. 228–230 ˝C; 1H-NMR (DMSO-d6) δ 9.34 (s, 1H, NH), 8.54 (d, J = 8.7 Hz, 1H, H4), 8.53 (s,
1H, H7), 7.91 (d, J = 8.7 Hz, 1H, H5), 5.29 (sept, J = 6.3 Hz, 1H, NCH), 3.30–3.25 (m, 1H, CH), 1.42 (d,
J = 6.3 Hz, 6H, CH3), 1.12–1.06 (m, 4H, CH); 13C-NMR (CDCl3) δ 163.2, 161.1, 160.7, 152.0, 147.2, 147.1,
133.2, 130.0, 126.7, 116.5, 70.4, 29.8, 21.8, 6.7 (2C) ; νmax 3275, 2971, 1668, 1641, 1586, 1494, 1455, 1352,
1313, 1145, 1109, 1054, 893, 823 cm´1; HRMS calcd for C16H17N4O2S [M + H]+ 329.1072 found 329.1065.
Isopropyl 8-(2-methoxyethyl)-9-oxo-8,9-dihydro[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate (15b): white
solid (56.3 mg, 65%), mp. 174–176 ˝C; 1H-NMR (DMSO-d6) δ 9.34 (br s, 1H, NH), 8.56 (d, J = 9.0 Hz, 1H,
H4), 8.54 (s, 1H, H7), 7.92 (d, J = 9 .0 Hz, 1H, H5), 5.29 (sept, J = 7.0 Hz, 1H, OCH), 4.30 (t, J = 5.1 Hz, 2H,
OCH2), 3.68 (t, J = 5.1 Hz, 2H, NCH2), 3.27 (s, 3H, OCH3), 1.41 (d, J = 7.0 Hz, 6H, 2x CH3); 13C-NMR
(DMSO-d6) δ 161.5, 159.0, 158.8, 151.0, 148.9, 147.6, 131.8, 129.6, 126.8, 115.9, 69.5, 68.9, 58.1, 45.9, 21.4
(2C); νmax 3278, 2981, 2928, 1658, 1641, 1588, 1350, 1140, 1111, 1052, 889, 837 cm´1; HRMS calcd for
C16H19N4O3S [M + H]+ 347.1178 found 347.1170.
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Isopropyl 8-(3-methoxypropyl)-9-oxo-8,9-dihydro[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate (15c): white
solid (81 mg, 90%), mp. 162–164 ˝C; 1H-NMR (DMSO-d6) δ 9.34 (s, 1H, NH), 8.59 (s, 1H, H7), 8.55 (d,
J = 9.0 Hz, 1H, H4), 7.92 (d, J = 9.0 Hz, 1H, H5), 5.28 (sept, J = 6.0 Hz, 1H, CH), 4.17 (t, J = 6.9 Hz, 2H,
OCH2), 3.40 (t, J = 6.0 Hz, 2H, NCH2), 3.28 (s, 3H, OCH3), 2.00 (dt, J = 6.9, 6.0 Hz, 2H, CH2), 1.40 (d,
J = 6.0 Hz, 6H, CH3), 13C-NMR (DMSO-d6) δ 161.4, 159.1, 158.9, 150.9, 148.7, 147.6, 131.7, 129.5, 126.8,
115.9, 69.5, 69.1, 57.9, 44.4, 28.2, 21.4 (2C); νmax 3275, 2993, 2939, 1663, 1582, 1340, 1112, 1058, 830 cm´1;
HRMS calcd for C17H21N4O3S [M + H]+ 361.1331 found. 361.1334.
3.3. In Vitro Kinase Preparation and Assays [25]
3.3.1. Buffers
Buffer A: MgCl2 (10 mM), 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’- tetraacetic
acid (EGTA), 1 mM dithiothreitol (DTT), 25 mM Tris-HCl pH 7.5, 50 µg heparin/mL. Buffer
B: β-Glycerophosphate (60 mM), 30 mM p-nitrophenylphosphate, 25 mM 3-(N-morpholino)
propanesulfonic acid (Mops) (pH 7.2), 5 mM EGTA, 15 mM MgCl2, 1 mM DTT, 0.1 mM sodium vanadate.
3.3.2. Kinase Preparations and Assays
Kinase activities were assayed in triplicates in buffer A or B, for 30 min. at 30 ˝C, at a final
adenosine triphosphate (ATP) concentration of 15 µM. Blank values were substracted and activities
expressed in % of the maximal activity, i.e., in the absence of inhibitors. Controls were performed with
appropriate dilutions of dimethylsulfoxide (DMSO). IC50 values were calculated from dose-response
curves established by Sigma-Plot graphs. The GSK-3, CK1, DYRK1A and CLK1 peptide substrates
were obtained from Proteogenix (Oberhausbergen, France).
CDK5/p25. (Human, recombinant) was prepared as previously described [21]. Its kinase activity
was assayed in buffer A, with 1 mg of histone H1/mL, in the presence of 15 µM [γ-33P] ATP
(3000 Ci/mmol; 10 mCi/mL) in a final volume of 30 µL. After 30 min incubation at 30 ˝C, 25 µL
aliquots of supernatant were spotted onto sheets of P81 phosphocellulose paper (Whatman) and
20 s later, the filters were washed eight times (for at least 5 min each time) in a solution of 10 mL
phosphoric acid/L of water. The wet filters were counted in the presence of 1 mL ACS (Amersham,
UK) scintillation fluid.
GSK-3α/β. (Porcine brain, native) was assayed, as described for CDK5/p25 but in buffer A
and using a GSK-3 specific substrate (GS-1: YRRAAVPPSPSLSRHSSPHQpSEDEEE) (pS stands for
phosphorylated serine) [36].
CK1δ/ε. (Porcine brain, native) was assayed as described for CDK5/p25 but using the CK1-specific
peptide substrate RRKHAAIGpSAYSITA [37].
DYRK1A. (Rat, recombinant, expressed in E. coli as a glutathione transferase (GST) fusion
protein) was purified by affinity chromatography on glutathione-agarose and assayed, as described for
CDK5/p25 using Woodtide (KKISGRLSPIMTEQ) (1.5µg/assay) as a substrate.
CLK1. (Human, recombinant, expressed in E. coli as GST fusion protein) was assayed in buffer A
(+0.15 mg BSA/mL) with RS peptide (GRSRSRSRSRSR) (1 µg/assay).
4. Conclusions
A library of thirty-three novel thiazolo[5,4-f ]quinazoline derivatives 11a–c, 12a–n, 13a–h,
14a–e, 15a–c has been rapidly prepared, using microwave-assisted technology when efficient
heating was needed. In order to have an efficient route to these variously 8-substituted
thiazolo[5,4-f ]quinazolin-9(8H)-ones, a rational multistep synthesis of methyl 6-amino-2-cyano-
benzo[d]thiazole-7-carboxylate (1) was developed and optimized to the multigram scale, affording
large quantities of a versatile and efficient precursor for the various target molecules in this study.
The inhibitory potency of the final products against five kinases involved in AD was evaluated.
Our study demonstrates that some molecules of the 12 and 13 series described in this paper are
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particularly promising for the development of new multi-target inhibitors of kinases. The most
active compounds showed nanomolar IC50 values for CLK1, DYRK1A and GSK-3α/β over the other
tested enzymes. Although affinities of these compounds for these three kinases are not negligible,
optimization is still needed and this paper allows us to consider further SAR studies for the design of
more efficient inhibitors of these targeted kinases.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
5/578/s1.
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